NGeneBio Shareholders Approve 66.67% Free Reduction to Offset Deficit, Raising Concerns Over Shareholder Value

NGeneBio shareholders approved a 66.67% free reduction at the extraordinary general meeting on June 9, 2026, to offset accumulated deficits. The 3:1 reverse stock split reduces outstanding shares from 26,809,750 to 8,936,583 and capital from 26.8 billion KRW to 8.9 billion KRW.
The record date is June 24, 2026, with trading suspended from June 23 to July 12. Shareholders lose two-thirds of their shares without compensation, leading to short-term price volatility and liquidity risk during the suspension period.
The company reported a turnaround with separate revenue of 790.2 billion KRW, operating profit of 97.7 billion KRW, and maintains a healthy financial structure with a debt ratio of 49.8% and current ratio of 211.7%. Treasury shares of 22.31% support future shareholder returns.
[AI Summary]NGeneBio's free reduction aims to improve financial health by eliminating deficits, with expected post-reduction per-share value increase. However, low shareholder turnout of 31.1% raises governance concerns. Profit turnaround and large treasury shares provide downside support, but investors should watch for uncertainty during the trading halt.